68 citations
,
February 2019 in “Urology” Hormonal treatment in transgender women reduces semen quality, but stopping treatment may improve it.
54 citations
,
September 2013 in “Fertility and Sterility” This study found that discontinuing finasteride led to a significant increase in sperm counts for most men with reduced fertility, though hormone levels and other semen parameters remained unchanged.
June 2026 in “British Journal of Dermatology” This study reviewed human evidence on the effects of 5α-reductase inhibitors, finasteride and dutasteride, on semen parameters and gonadotrophins, finding finasteride causes mild, reversible changes, while dutasteride may lead to more pronounced and potentially less reversible impacts, suggesting caution for those planning to conceive.
April 2026 in “The Journal of Urology” This study found that prolonged use of finasteride and dutasteride in young men with androgenic alopecia is linked to a decline in semen quality over time, particularly affecting sperm motility and DNA integrity, with dutasteride showing a slightly greater impact than finasteride.
March 2025 in “Daehan saengsik uihak hoeji/Clinical and experimental reproductive medicine” This study found that long-term use of dutasteride in men taking it for androgenetic alopecia may lead to persistent decreases in semen volume and sperm motility, potentially impacting fertility, with significant impairment observed after 17.8 to 20.3 months of treatment.